UB Paderborn / Katalog / Suche / in CDI

1 – 16 von 16

Sortiert nach

Long‐term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A Critically Appraised Topic

British journal of dermatology (1951), 2019-04, Vol.180 (4), p.749-755

2019

Volltextzugriff (PDF)

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2021-09, Vol.157 (9), p.1047

2021

Volltextzugriff (PDF)

Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.478-485

2023

Volltextzugriff (PDF)

308 Incremental improvements after switching from dupilumab (DUPI) to upadacitinib (UPA) in the Heads Up open-label extension (OLE) study

Journal of investigative dermatology, 2022-08, Vol.142 (8), p.S53

2022

Volltextzugriff (PDF)

Analyse incrémentale sur l’amélioration des lésions cutanées avec upadacitinib versus dupilumab dans la dermatite atopique (AD) modérée à sévère : résultats de l’étude Heads Up

Revue française d'allergologie (2009), 2023-04, Vol.63 (3), p.103608, Article 103608

2023

Volltextzugriff (PDF)

RAPID QUALITY-OF-LIFE IMPROVEMENT WITH UPADACITINIB WITH OR WITHOUT TOPICAL CORTICOSTEROIDS (TCS) IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM 3 PHASE 3 STUDIES (MEASURE UP 1, MEASURE UP 2, AND AD UP)

ACTA DERMATO-VENEREOLOGICA, 2021, Vol.101, p.34

2021

Volltextzugriff (PDF)

Efficacy and safety of switching from dupilumab to upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension trial

BRITISH JOURNAL OF DERMATOLOGY, 2022, Vol.186 (4), p.E142

2022

Volltextzugriff (PDF)

CME examination

Journal of the American Academy of Dermatology, 2015-12, Vol.73 (6), p.945-945

2015

Volltextzugriff (PDF)

Upadacitinib vs. dupilumab in adults with moderate-to-severe atopic dermatitis: analysis of the Heads Up phase III trial

BRITISH JOURNAL OF DERMATOLOGY, 2021, Vol.185 (3), p.E123

2021

Volltextzugriff (PDF)

UPADACITINIB VERSUS DUPILUMAB IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF THE HEADS UP PHASE 3 TRIAL

ACTA DERMATO-VENEREOLOGICA, 2021, Vol.101, p.62

2021

Volltextzugriff (PDF)

Frontal fibrosing alopecia: A retrospective review of 19 patients seen at Duke University

Journal of the American Academy of Dermatology, 2013-05, Vol.68 (5), p.749-755

2013

Volltextzugriff (PDF)

Aprepitant: A novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma

Journal of the American Academy of Dermatology, 2012-11, Vol.67 (5), p.e198-e199

2012

Volltextzugriff (PDF)

Failure to Yield: Refractory Achalasia

The American journal of medicine, 2014, Vol.127 (1), p.34-35

2014

Volltextzugriff (PDF)

Transarterial embolization followed by surgical excision of skin lesions as treatment for angiolymphoid hyperplasia with eosinophilia

Journal of the American Academy of Dermatology, 2013-02, Vol.68 (2), p.e48-e49

2013

Volltextzugriff (PDF)

Diagnosis of herpes simplex virus-induced erythema multiforme confounded by previous infection with Mycoplasma pneumonia

Journal of drugs in dermatology, 2013-06, Vol.12 (6), p.707

2013

Volltextzugriff (PDF)

Progressive multifocal leukoencephalopathy and reversible progressive leukoencephalopathy syndrome in dermatologic therapy

Journal of drugs in dermatology, 2013-02, Vol.12 (2), p.e20

2013

Volltextzugriff (PDF)

1 – 16 von 16

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(12)
Tagungsberichte
(4)

Sprache

Englisch
(15)
Französisch
(1)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Long‐term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A Critically Appraised Topic

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)

308 Incremental improvements after switching from dupilumab (DUPI) to upadacitinib (UPA) in the Heads Up open-label extension (OLE) study

Analyse incrémentale sur l’amélioration des lésions cutanées avec upadacitinib versus dupilumab dans la dermatite atopique (AD) modérée à sévère : résultats de l’étude Heads Up

RAPID QUALITY-OF-LIFE IMPROVEMENT WITH UPADACITINIB WITH OR WITHOUT TOPICAL CORTICOSTEROIDS (TCS) IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM 3 PHASE 3 STUDIES (MEASURE UP 1, MEASURE UP 2, AND AD UP)

Efficacy and safety of switching from dupilumab to upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension trial

CME examination

Upadacitinib vs. dupilumab in adults with moderate-to-severe atopic dermatitis: analysis of the Heads Up phase III trial

UPADACITINIB VERSUS DUPILUMAB IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF THE HEADS UP PHASE 3 TRIAL

Frontal fibrosing alopecia: A retrospective review of 19 patients seen at Duke University

Aprepitant: A novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma

Failure to Yield: Refractory Achalasia

Transarterial embolization followed by surgical excision of skin lesions as treatment for angiolymphoid hyperplasia with eosinophilia

Diagnosis of herpes simplex virus-induced erythema multiforme confounded by previous infection with Mycoplasma pneumonia

Progressive multifocal leukoencephalopathy and reversible progressive leukoencephalopathy syndrome in dermatologic therapy

Suchergebnisse filtern